4007 completed, 375 terminated, 152 recruiting, 150 withdrawn. 1396 Phase 1, 1265 Phase 2, 1099 Phase 3, 538 Phase 4, 209 Not applicable.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE. belantamab mafodotin to the existing stable standard background therapy - SLE - Systemic Lupus Erythematosus | Phase 2 | Not yet recruiting | Medical Association for the Study of Cancer Biology and Treatment | 12 | 2027-02-01 | 2026-09-28 |
| A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial | Phase 1 | Not yet recruiting | GlaxoSmithKline | 60 | 2027-01-25 | 2026-07-16 |
| Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | 108 | 2026-12-01 | 2026-09-21 |
| A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors RZV vaccine, Placebo - Cardiovascular Disease | Phase 3 | Not yet recruiting | GlaxoSmithKline | 16390 | 2026-11-30 | 2026-10-13 |
| Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer Dostarlimab, Carboplatin and paclitaxel - Endometrial Carcinoma, Neoplasms, Endometrial | Phase 3 | Not yet recruiting | GlaxoSmithKline | 378 | 2026-11-12 | 2026-10-19 |
| A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib Velzatinib - Healthy Participants, Gastrointestinal Neoplasms | Phase 1 | Not yet recruiting | GlaxoSmithKline | 40 | 2026-11-10 | 2026-10-06 |
| Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) | Phase 4 | Not yet recruiting | SWOG Cancer Research Network | 268 | 2026-11-01 | 2026-09-17 |
| A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib Velzatinib - Healthy Participants, Gastrointestinal Neoplasms | Phase 1 | Not yet recruiting | GlaxoSmithKline | 30 | 2026-10-23 | 2026-10-09 |
| A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment Belantamab mafodotin, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 | Not yet recruiting | GlaxoSmithKline | 20 | 2026-10-23 | 2026-05-27 |
| A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events Placebo, Adjuvanted RZV vaccine, Adjuvanted RSVPreF3 vaccine - Cardiovascular Disease | Phase 2 | Not yet recruiting | GlaxoSmithKline | 450 | 2026-10-23 | 2026-10-20 |
| A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants Velzatinib, Cyclosporine, Omeprazole - Healthy Participants, Gastrointestinal Neoplasms | Phase 1 | Not yet recruiting | GlaxoSmithKline | 36 | 2026-10-16 | 2026-10-07 |
| A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care Belantamab SC, Belantamab IV, Recombinant Human Hyaluronidase PH20 (rHuPH20) - Multiple Myeloma | Phase 1 | Not yet recruiting | GlaxoSmithKline | 22 | 2026-10-16 | 2026-08-03 |
| A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST) Velzatinib - Gastrointestinal Neoplasms | Phase 2 | Not yet recruiting | GlaxoSmithKline | 72 | 2026-10-13 | 2026-09-28 |
| J-LINX: Japan LINerixibat eXtension Study Linerixibat - Pruritus | Phase 3 | Not yet recruiting | GlaxoSmithKline | 40 | 2026-10-09 | 2026-10-06 |
| Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03] Mocertatug rezetecan, Bevacizumab - Ovarian Neoplasms | Phase 3 | Not yet recruiting | GlaxoSmithKline | 720 | 2026-10-09 | 2026-10-02 |
| Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. Belantamab Mafodotin, Pomalidomide, Dexamethasone - Relapsed / Refractory Multiple Myeloma | Phase 2 | Not yet recruiting | Polish Myeloma Consortium | 228 | 2026-10-01 | 2026-08-06 |
| A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age mRNA Seasonal Flu vaccine, Comparator 1, Comparator 2 - Influenza, Human | Phase 3 | Recruiting | GlaxoSmithKline | 3000 | 2026-10-01 | 2026-10-09 |
| Prospective Registry of Exposure to Gepotidacin (PREG) None (Observational study) - Sexually Transmitted Diseases | Not yet recruiting | GlaxoSmithKline | 614 | 2026-09-30 | 2026-09-30 | |
| A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) GSK5784283, Placebo, Standard of Care - Nasal Polyps | Phase 3 | Recruiting | GlaxoSmithKline | 218 | 2026-09-28 | 2026-10-14 |
| A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02) Mocertatug rezetecan, Dostarlimab, Pembrolizumab - Neoplasms, Endometrial | Phase 3 | Recruiting | GlaxoSmithKline | 610 | 2026-09-24 | 2026-10-15 |
Showing 20 of 4947. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (338) · Asthma (314) · Influenza, Human (200) · Neoplasms (166) · Diabetes Mellitus, Type 2 (151) · Hepatitis B (150) · Infections (146) · Acquired Immunodeficiency Syndrome (133) · HIV Infections (130) · Breast Neoplasms (106) · Tetanus (103) · Diphtheria (98) · Haemophilus Infections (83) · Meningococcal Infections (78) · Papillomavirus Infections (72)
Lapatinib (115) · Fluticasone (112) · pazopanib (92) · fluticasone furoate (71) · Rosiglitazone (64) · Data Collection (62) · Fluticasone-Salmeterol Drug Combination (62) · belimumab (60) · dostarlimab (60) · Topotecan (58) · mepolizumab (58) · dolutegravir (57) · Blood Specimen Collection (55) · Salmeterol Xinafoate (54) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (54)
United States (2120) · United Kingdom (814) · Germany (718) · Canada (623) · Spain (517) · France (448) · Australia (412) · Italy (377) · Belgium (374) · South Korea (343) · Japan (339) · Netherlands (334) · Poland (316) · Russia (299) · Argentina (246)
Roger K Cady, MD (6) · Anthony Greco, MD (4) · Christian Tielemans, MD, PhD (3) · David V Condoluci, DO (3) · Evangelos Terpos, Prof (3)
PMID 41276263, PMID 25387217, PMID 36005278, PMID 27881132, PMID 36472162, PMID 24314123, PMID 34628605, PMID 34741731, PMID 37781954, PMID 26704701, PMID 28683300, PMID 30954640, PMID 32710245, PMID 34473343, PMID 34531304, PMID 38775637, PMID 38780109, PMID 39115551, PMID 39208825, PMID 20526599, PMID 24408395, PMID 24443277, PMID 24918790, PMID 26446943, PMID 31824976, PMID 33687069, PMID 34098955, PMID 34523118, PMID 38216728, PMID 38724182, PMID 39377226, PMID 40190112, PMID 41461999, PMID 23054212, PMID 23254770, PMID 24731816, PMID 24966061, PMID 24998880, PMID 25424785, PMID 25424918, PMID 26873055, PMID 27093773, PMID 27796912, PMID 29465480, PMID 31047111, PMID 31164116, PMID 31197640, PMID 31251094, PMID 31302695, PMID 31321713
2016 (55), 2017 (51), 2023 (48), 2015 (41), 2025 (37), 2014 (31), 2018 (23), 2009 (22), 2008 (18), 2019 (14), 2004 (8), 2005 (7), K23HD045386 (2), P30CA138292 (2), U01AI065683 (2)